Published: 1st July 2015
The European clinical diagnostics businesses, Labco and SYNLAB, today announced that Dr. Bartl Wimmer will be appointed as Group Chief Executive and Philippe Charrier as Executive Chairman of the combined group.
This announcement follows the acquisitions of Labco and SYNLAB by European private equity firm Cinven in May and June respectively. These positions will be effective once Cinven’s acquisitions of both Labco and SYNLAB have completed, which is expected to be in September 2015.
Dr. Bartl Wimmer is currently Chief Executive Officer of SYNLAB. He was the co-founder of the SYNLAB business in 1998 and has acted as Managing Director since its establishment. Since January 2010, he has held the position of CEO with responsibility for the successful acquisition and integration of numerous medical diagnostics laboratories across Germany and Europe.
Philippe Charrier is currently Chief Executive Officer of Labco. He joined the Board of Labco in 2011 and was previously CEO of Oenobiol, the personal beauty care product firm. During 1999 to 2006, he was CEO of P&G France. During his tenure as CEO, Philippe Charrier has overseen significant growth and expansion at Labco building it into the pre-eminent operator of clinical laboratories in Western Europe.
I am delighted to be appointed Group CEO of the combined Labco/SYNLAB business. Both these companies are highly successful operators of medical diagnostics laboratories across Europe and have grown strongly in recent years. “The combination of these businesses will enable us to continue developing first class medical diagnostics and allow us to benefit from genuine benefits of scale where we can provide diagnostic services more efficiently to patients and payors. Labco has an excellent team and reputation and I am looking forward to working closely with Philippe Charrier as Executive Chairman.Dr Bartl Wimmer
The European clinical diagnostics sector is continuing to grow and the combined Labco/SYNLAB Group is extremely well positioned to benefit from the increasing demand for clinical diagnostics services, particularly given the under penetrated and highly fragmented European market. The combined Group will have the strongest medical capabilities in Europe, and will be able to deliver new tests to market to provide improved patient outcomes.
SYNLAB is a highly respected operator within the market and, as Executive Chairman, it will be my role to oversee the gradual combination of the two businesses in a way that harnesses the best of both operations. I am looking forward to working with Bartl Wimmeras Group CEO and believe that together the combined group has an exciting future ahead.
The completion of the Labco and SYNLAB acquisitions remain subject to the satisfaction of customary regulatory approval. These appointments are subject to the completion of the contemplated change of control and the forthcoming integration of these businesses.Philippe Charrier